Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 7/20 | 0.52 |
| ▸ | PTGES | O14684 | 4/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.51 |
| ▸ | PPARG | P37231 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | RARA | P10276 | 1/20 | 0.44 |
| ▸ | RARB | P10826 | 1/20 | 0.44 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1107732 | 0.91 | GCK (0.53) | GCKPTGESALOX5PPARGMAPT | |
| SCHEMBL1042331 | 0.88 | LMNA (0.55) | GCKRAB9ALMNAHPGDRARA | |
| SCHEMBL2666576 | 0.82 | PLA2G2A (0.47) | GCKPTGESALOX5PPARGMAPT | |
| SCHEMBL9325175 | 0.81 | KMT2A (0.55) | GCKPTGESALOX5PPARGMAPT | |
| SCHEMBL1107666 | 0.81 | GCK (0.58) | GCKPTGESALOX5PPARGRARA | |
| SCHEMBL3604602 | 0.81 | PPARA (0.46) | GCKALOX5PPARGLMNAHPGD | |
| SCHEMBL1107570 | 0.81 | GCK (0.55) | GCKRARARARB | |
| SCHEMBL12742914 | 0.80 | PTGES (0.52) | GCKPTGESALOX5PPARGRARA | |
| SCHEMBL1427108 | 0.80 | LMNA (0.54) | GCKLMNAHPGDRARARARB | |
| SCHEMBL1042436 | 0.80 | LMNA (0.54) | GCKLMNAHPGDRARARARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7642263-B2 | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes | ASTRAZENECA AB (SE) | 2010-01-05 | — | — | US | disclosed |
| US-20090029905-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029905-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | GCK, GCKR, GK | GCK 1/4885PTGES 70/4885ALOX5 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.